Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/58215
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCatharina Buschen_US
dc.contributor.authorDinah Zuren_US
dc.contributor.authorSamantha Fraser-Bellen_US
dc.contributor.authorInês Laínsen_US
dc.contributor.authorAna Rita Santosen_US
dc.contributor.authorMarco Lupidien_US
dc.contributor.authorCarlo Caginien_US
dc.contributor.authorPierre Henry Gabrielleen_US
dc.contributor.authorAude Couturieren_US
dc.contributor.authorValérie Mané-Tautyen_US
dc.contributor.authorErmete Giancipolien_US
dc.contributor.authorGiuseppe D.Amico Riccien_US
dc.contributor.authorZafer Cebecien_US
dc.contributor.authorPatricio J. Rodríguez-Valdésen_US
dc.contributor.authorVoraporn Chaikitmongkolen_US
dc.contributor.authorAtchara Amphornphrueten_US
dc.contributor.authorIsaac Hindien_US
dc.contributor.authorKushal Agrawalen_US
dc.contributor.authorJay Chhablanien_US
dc.contributor.authorAnat Loewensteinen_US
dc.contributor.authorMatias Iglickien_US
dc.contributor.authorMatus Rehaken_US
dc.date.accessioned2018-09-05T04:21:15Z-
dc.date.available2018-09-05T04:21:15Z-
dc.date.issued2018-08-01en_US
dc.identifier.issn14325233en_US
dc.identifier.issn09405429en_US
dc.identifier.other2-s2.0-85046451948en_US
dc.identifier.other10.1007/s00592-018-1151-xen_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046451948&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/58215-
dc.description.abstract© 2018, Springer-Verlag Italia S.r.l., part of Springer Nature. Aims: To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEGF injections in a real-world setting. Methods: To be included in this retrospective multicenter, case–control study, eyes were required: (1) to present with early refractory DME, as defined by visual acuity (VA) gain ≤ 5 letters or reduction in central subfield thickness (CST) ≤ 20%, after a loading phase of anti-VEGF therapy (three monthly injections) and (2) to treat further with (a) anti-VEGF therapy or (b) DEX implant. Main outcome measures were change in visual acuity (VA) and central subfield thickness (CST) at 12 months. Due to imbalanced baseline characteristics, a matched anti-VEGF group was formed by only keeping eyes with similar baseline characteristics as those in the DEX group. Results: A total of 110 eyes from 105 patients were included (anti-VEGF group: 72 eyes, DEX group: 38 eyes). Mean change in VA at 12 months was − 0.4 ± 10.8 letters (anti-VEGF group), and + 6.1 ± 10.6 letters (DEX group) (P = 0.004). Over the same period, mean change in CST was + 18.3 ± 145.9 µm (anti-VEGF group) and − 92.8 ± 173.6 µm (DEX group) (P < 0.001). Eyes in the DEX group were more likely to gain ≥ 10 letters (OR 3.71, 95% CI 1.19–11.61, P = 0.024) at month 12. Conclusions: In a real-world setting, eyes with DME considered refractory to anti-VEGF therapy after three monthly injections which were switched to DEX implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with anti-VEGF therapy.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleShall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edemaen_US
dc.typeJournalen_US
article.title.sourcetitleActa Diabetologicaen_US
article.volume55en_US
article.stream.affiliationsUniversitatsklinikum Leipzig und Medizinische Fakultaten_US
article.stream.affiliationsTel Aviv Sourasky Medical Centeren_US
article.stream.affiliationsTel Aviv University, Sackler Faculty of Medicineen_US
article.stream.affiliationsThe University of Sydneyen_US
article.stream.affiliationsUniversidade de Coimbra, Faculdade de Medicinaen_US
article.stream.affiliationsAssociation for Innovation and Biomedical Research on Lighten_US
article.stream.affiliationsHarvard Medical Schoolen_US
article.stream.affiliationsInstituto Politcnico do Portoen_US
article.stream.affiliationsUniversita degli Studi di Perugiaen_US
article.stream.affiliationsCentre Hospitalier Universitaire de Dijonen_US
article.stream.affiliationsCentre des Sciences du Gout et de l'Alimentationen_US
article.stream.affiliationsUniversite Paris 7- Denis Dideroten_US
article.stream.affiliationsUniversita degli Studi di Sassarien_US
article.stream.affiliationsIstanbul Tip Fakultesien_US
article.stream.affiliationsTecnologico de Monterreyen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsRangsit Universityen_US
article.stream.affiliationsL.V. Prasad Eye Institute Indiaen_US
article.stream.affiliationsTel Aviv Universityen_US
article.stream.affiliationsUniversidad de Buenos Airesen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.